Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 6.68 -0.15% -0.01
MACK closed down 0.15 percent on Monday, March 25, 2019, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Down
See historical MACK trend table...

Date Alert Name Type % Chg
Mar 25 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 25 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 25 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 25 Narrow Range Bar Range Contraction 0.00%
Mar 25 NR7 Range Contraction 0.00%
Mar 25 Inside Day Range Contraction 0.00%
Mar 25 Down 3 Days in a Row Weakness 0.00%
Mar 22 20 DMA Support Bullish -0.15%
Mar 22 Wide Range Bar Range Expansion -0.15%
Mar 22 Upper Bollinger Band Walk Strength -0.15%

Older signals for MACK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Antibodies Chemotherapy Cancers Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu University Of California Erb B3 Mm 151
Is MACK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.535
52 Week Low 3.34
Average Volume 73,366
200-Day Moving Average 5.4015
50-Day Moving Average 5.9351
20-Day Moving Average 6.5353
10-Day Moving Average 6.8986
Average True Range 0.3323
ADX 55.4
+DI 27.4514
-DI 20.8799
Chandelier Exit (Long, 3 ATRs ) 6.5031
Chandelier Exit (Short, 3 ATRs ) 6.8769
Upper Bollinger Band 7.4048
Lower Bollinger Band 5.6658
Percent B (%b) 0.58
BandWidth 26.609337
MACD Line 0.3163
MACD Signal Line 0.3293
MACD Histogram -0.013
Fundamentals Value
Market Cap 88.7 Million
Num Shares 13.3 Million
EPS 32.12
Price-to-Earnings (P/E) Ratio 0.21
Price-to-Sales 1.06
Price-to-Book 1.44
PEG Ratio 0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.91
Resistance 3 (R3) 6.92 6.87 6.87
Resistance 2 (R2) 6.87 6.81 6.86 6.85
Resistance 1 (R1) 6.77 6.77 6.75 6.76 6.84
Pivot Point 6.72 6.72 6.70 6.71 6.72
Support 1 (S1) 6.62 6.66 6.60 6.61 6.52
Support 2 (S2) 6.57 6.62 6.56 6.51
Support 3 (S3) 6.47 6.57 6.49
Support 4 (S4) 6.46